您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > AS8351
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
AS8351
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
AS8351图片
CAS NO:796-42-9
包装与价格:
包装价格(元)
10mg电议
50mg电议

产品介绍
AS8351 (NSC51355) 是一种 KDM5B 抑制剂,可诱导和维持活性染色质标记,以促进心肌细胞样细胞的诱导。
Cas No.796-42-9
别名NSC51355
化学名(E)-N'-((2-hydroxynaphthalen-1-yl)methylene)isonicotinohydrazide
Canonical SMILESOC(C=CC1=CC=CC=C12)=C2/C([H])=N/NC(C3=CC=NC=C3)=O
分子式C17H13N3O2
分子量291.3
溶解度≥ 29.1mg/mL in DMSO
储存条件Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

IC50: N/A

AS8351 is a histone demethylase inhibitor.

Histone methylation is considered as a more dynamic modification with the discovery of Histone demethylases. Removal of methyl groups is mediated by LSD1, PAD14 and JmjC domain containing proteins.

In vitro: In a previous study, in order to identify indispensable factors for human fibroblasts, the authors removed combined compounds one by one and treated cells with the remaining compounds. Results showed that the number of beating clusters was significantly reduced by removal of seven compounds including AS8351. Moreover, these seven compounds inlcuding AS8351 were sufficient and necessary to induce cardiac reprogramming efficiently. The authors then investigated the role of the reprogramming compound of AS8351 and the results showed that AS8351 and its functional analogs could affect epigenetic modifications by competing with α- ketoglutarate for chelating iron/Fe(II) in some epigenetic enzymes, including the JmjC-domain-containing histone demethylases that require α-KG and iron as co-factors. In addition, the authors abrogated each of the 22 genes in the JmjC-KDM family by small hairpin RNAs and found that only with KDM5B knockdown, or using a KDM5B inhibitor, PBIT could phenocopy AS8351 in generating ciCMs, indicating that it might be a target of AS8351 [1].

In vivo: Currently, there is no animal in vivo data reported.

Clinical trial: Up to now, AS8351 is still in the preclinical development stage.

Reference:
[1] N.  Cao, Y. Huang, J. Zheng,et al.Conversion of human fibroblasts into functional cardiomyocytes by small molecules.Science 352(6290),1216-1220(2016).